- Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
- Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
- Arbutus to Participate in Jefferies Global Healthcare Conference
- Arbutus to Present Imdusiran Data at EASL Congress 2024
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
More ▼
Key statistics
On Monday, Arbutus Biopharma Corp (I9DN:DUS) closed at 2.89, -12.10% below its 52-week high of 3.29, set on Jun 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.90 |
---|---|
High | 2.92 |
Low | 2.89 |
Bid | -- |
Offer | -- |
Previous close | 2.89 |
Average volume | 200.00 |
---|---|
Shares outstanding | 188.72m |
Free float | 146.66m |
P/E (TTM) | -- |
Market cap | 603.90m USD |
EPS (TTM) | -0.4393 USD |
Data delayed at least 15 minutes, as of Jun 10 2024 18:32 BST.
More ▼